We believe that 2PAT-301 and 2PAT-401 can minimize the death and suffering associated with myocardial infarction, stroke and brain injuries and extend patients’ useful lifetime.

 Myocardial Infarction - There are over 1.2 million hospital admissions in the US every year for acute coronary syndrome, 3.2 million including Europe and Japan.  Myocardial infarction leaves a damaged and poorly performing heart, often leading to subsequent hospital admissions, heart failure and death.  2PAT-301, administered as soon after the event as possible and again through the catheter at percutaneous coronary intervention (PCI), will minimize the IRI damage through its activation of the c-MET receptor.

Stroke - 2PAT-401, administered as soon as possible after the event, will stabilize the blood brain barrier and protect the neurovascular unit against damage.  2PAT-401 could be the first therapy to protect ischemic brain tissue independent of vessel status.  It can reduce infarct size in patients who are ineligible for thrombolysis or thrombectomy and may enhance the safety and effectiveness of existing reperfusion strategies.  2PAT-401 will also initiate repair, stimulating angiogenesis, extending new axons, stimulating axon branching and stabilizing new synapses.